Options include: brand-name Wegovy or Zepbound (covered by some insurance plans), the new Medicare GLP-1 Bridge ($50/month for eligible Medicare beneficiaries starting July 2026), Foundayo (orforglipron, $149/month oral pill), manufacturer patient assistance programs, or transitioning to a 503A compounding pharmacy if a documented clinical need exists (such as an allergy to an inactive ingredient)
I talked about this with Andrea Traina
Possible bowel obstruction
New England Journal of Medicine, 322(12), 816-821
After investigating over 1,000 different plant compounds in vitro, the researchers concluded that a native New Zealand hops extract produced the strongest TAS2R stimulation and consequential enhanced release of anorexigenic (GLP-1, CCK and PYY) hormonal response, indicating the strongest appetite suppressant effect
To compare pre- and post-treatment data, we used the paired Students t-test when the assumption of normality was met